The NIH XXXX /Chondroitin Arthritis Intervention Trial (GAIT).

@entity1 @entity12698 @entity571 @entity4823 @entity12006 @entity12007 @entity158 @entity597
Americans continue to spend millions of dollars annually on @entity4823 and chondroitin for symptoms of @entity571 . These agents are classified as dietary supplements, not as drugs, per se. Therefore, they do not meet the requirements of the FDA to be classified as drugs. This study was designed to determine if @entity4823 and @entity12007 are effective for @entity158 . This report was adapted from an online publication by the National Center for Complimentary and Alternative Medicine of the National Institutes of Health to inform the general public about the GAIT trial and its findings. @entity1 taking the positive control, @entity12698 , experienced statistically significant @entity158 relief versus placebo, about 70% of those taking @entity12698 had a 20% or greater reduction in @entity158 versus about 60% for placebo. Overall, there were no significant differences between the other treatments tested and placebo. For a subset of @entity1 with moderate-to-severe @entity158 , @entity4823 combined with @entity12006 provided statistically significant @entity158 relief compared with placebo, about 79% had a 20% or greater reduction in @entity158 versus about 54% for placebo. According to the researchers, because of the small size of this subgroup these findings should be considered preliminary and need to be confirmed in further studies. For @entity1 in the mild @entity158 subset, @entity4823 and chondroitin @entity597 together or alone did not provide statistically significant @entity158 relief.
